AML Blood Test – A new method for the early detection and prognosis of acute myeloid leukemia
Diagnosing leukemia, especially acute myeloid leukemia (AML), is hindered due to the unspecific symptoms of the disease. Unfortunately misdiagnoses and mistreatments with antiviral or antibiotic medicine lead to a loss of precious time in fighting against this type of cancer.
Scientists from the University of Bonn tackled this challenge by developing a blood test. This test is based on one of the most advanced approaches of gene expression profiling: gene signatures. By adaptive learning and simulation the new blood test for acute myeloid leukemia (AML-BT) was generated. With an “RNA-fingerprint”, the analysis of the different indicator RNAs – showing a decreased or increased expression rate as indication for AML – can be conducted and used for a reliable diagnosis.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Peptides on Interstellar Ice
A research team led by Dr Serge Krasnokutski from the Astrophysics Laboratory at the Max Planck Institute for Astronomy at the University of Jena had already demonstrated that simple peptides…
A new look at the consequences of light pollution
GAME 2024 begins its experiments in eight countries. Can artificial light at night harm marine algae and impair their important functions for coastal ecosystems? This year’s project of the training…
Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work
Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…
